Latest Oncology Diagnostics News

Page 3 of 3

Telix Surpasses FY24 Revenue Targets with US$142M Q4 Surge

Telix Pharmaceuticals has exceeded its full-year 2024 revenue guidance, driven by strong sales of its prostate cancer diagnostic Illuccix® and strategic pipeline advancements.

Ada Torres

13 Jan 2025

Browse the archive

Full archive

Oct 2026 Sept 2026 Aug 2026 July 2026 June 2026 May 2026 Apr 2026 Mar 2026

Top